Law360, New York (April 04, 2011, 6:05 PM ET) -- Myriad Genetics Inc. tried to persuade the Federal Circuit on Monday that seven of its patents for isolated human genes were not invalid for merely being products of nature, as a lower court ruled.
A three-judge panel of the U.S. Court of Appeals for the Federal Circuit heard the Association for Molecular Pathology argue, in response, that the seven isolated gene patents at issue were not materially different from their original form in the human body.
Judge Robert W. Sweet's March ruling in the U.S. District...
Myriad Pushes For Isolated DNA Patents In Fed. Circ.
To view the full article, take a free trial now.
